Idorsia Ltd. & Idorsia Pharmaceuticals, US Inc. i kēia lā ua hoʻolaha aku ʻo QUVIVIQ™ (daridorexant) CIV 25 mg a me 50 mg papa i kēia manawa ke kūʻai aku nei no nā poʻe maʻi makua me ka insomnia, kahi i hōʻike ʻia e ka pilikia me ka hāʻule ʻana a i ʻole ka hiamoe ʻana.
ʻO ka insomnia kahi kūlana o ka hana lolo nui i ka wā hiamoe, a ua hōʻike ʻia nā haʻawina e ʻoi aku ka ikaika o nā wahi o ka lolo e pili ana i ka wakefulness i ka wā hiamoe i nā poʻe maʻi me ka insomnia. ʻO ka insomnia ka maʻi hiamoe maʻamau, e pili ana i ka ʻoi aku ma mua o 25 miliona mau mākua ma US. I ka wā lōʻihi, pili ka insomnia me nā maʻi olakino koʻikoʻi, e like me nā maʻi psychiatric, maʻi cardiovascular, hoʻohana i ka lāʻau a me ka dementia.2
ʻO QUVIVIQ he mea kū'ē i ka orexin receptor antagonist, kahi e ālai ai i ka hoʻopaʻa ʻana o nā neuropeptides orexins hoʻāla ala a manaʻo ʻia e hoʻohaʻahaʻa i ka hiamoe nui ʻana i ka insomnia. ʻehiku mau hola i koe ma mua o ke ala ʻana i manaʻo ʻia.
Ua ʻōlelo ʻo Patricia Torr, Pelekikena a me Luna Nui o Idorsia US:
"Ma hope o nā makahiki i hoʻolaʻa ʻia i ka noiʻi ʻana i ka ʻepekema o ka hiamoe a me ka ʻōnaehana orexin, i kēia lā he mea koʻikoʻi koʻikoʻi no Idorsia, ʻoiai ʻo ka huahana mua o ka ʻoihana ma US i loaʻa i nā maʻi."
He aha e lawe ʻia mai kēia ʻatikala:
- “After years dedicated to researching the science of sleep and the orexin system, today is a momentous milestone for Idorsia, as the company’s first product in the US is now available to patients.
- Insomnia is a condition of overactive brain activity during sleep, and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia.
- QUVIVIQ is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness in insomnia.
